Skip to main content
    A

    AstraZeneca PLC (AZN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $166.73
    +4.70 (+2.90%)

    Market Cap: $251.29B

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    -0.19%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$1.15
    Range$1.15 - $1.15
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$1.17-1.8%
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current$1.15
    Revenue Consensus
    $16.0B
    Range$15.8B - $16.3B
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$6.38
    Range$6.34 - $6.45
    3 analysts
    Revenue Consensus
    $17.0B
    Range$16.1B - $18.0B
    26 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$6.38---
    Sep 26EST
    		-$1.15---
    Jun 26
    Reported Jul 27
    		$2.63$2.50+5.20%Beat+232.9%
    Mar 26
    Reported Apr 29
    		$1.29$1.27+1.57%Beat+3.2%
    Dec 25
    Reported Feb 10
    		$2.12$2.18-2.75%Miss-14.5%
    Sep 25
    Reported Nov 6
    		$1.19$1.13+5.31%Beat+13.3%
    Jun 25
    Reported Jul 29
    		$0.79$0.88-10.23%Miss-24.0%
    Mar 25
    Reported Apr 29
    		$1.25$1.12+11.61%Beat+26.3%
    Mar 25
    Reported Apr 29
    		$2.48$2.25+10.22%Beat+140.8%
    Dec 24
    Reported Feb 6
    		$1.05$1.04+0.96%Beat+43.8%
    Sep 24
    Reported Nov 12
    		$1.04$1.03+0.97%Beat+19.5%
    Jun 24
    Reported Jul 25
    		$0.99$0.99+0.00%Beat-8.3%
    Mar 24
    Reported Apr 25
    		$1.03$0.95+8.42%Beat+7.3%
    Dec 23
    Reported Feb 8
    		$0.73$0.76-3.95%Miss+5.8%
    Sep 23
    Reported Nov 9
    		$0.87$0.82+6.10%Beat+3.6%
    Jun 23
    Reported Jul 28
    		$1.08$0.97+11.34%Beat+25.6%
    Mar 23
    Reported Apr 27
    		$0.96$0.82+17.07%Beat+1.1%
    Dec 22
    Reported Feb 9
    		$0.69$0.68+1.47%Beat-17.9%
    Sep 22
    Reported Nov 10
    		$0.84$0.75+12.00%Beat+55.6%
    Jun 22
    Reported Jul 29
    		$0.86$1.04-17.31%Miss+91.1%
    Mar 22
    Reported Apr 29
    		$0.95$1.15-17.39%Miss+15.9%
    Dec 21
    Reported Feb 10
    		$0.84$0.99-15.15%Miss+37.7%
    Sep 21
    Reported Nov 12
    		$0.54$0.91-40.66%Miss+17.4%
    Jun 21
    Reported Jul 29
    		$0.45$0.69-34.78%Miss-6.2%
    Mar 21
    Reported Apr 30
    		$0.82$0.96-14.58%Miss+54.7%
    Dec 20
    Reported Feb 11
    		$0.61$0.76-19.74%Miss+155.7%
    Sep 20
    Reported Nov 5
    		$0.46$0.48-4.17%Miss-8.0%
    Jun 20
    Reported Jul 30
    		$0.48$0.40+20.00%Beat+29.7%
    Mar 20
    Reported Apr 29
    		$0.53$0.49+8.16%Beat+17.8%
    Dec 19
    Reported Feb 14
    		$0.24N/AN/ABeat-70.8%
    Sep 19
    Reported Oct 24
    		$0.50$0.41+21.95%Beat+38.9%
    Jun 19
    Reported Jul 25
    		$0.37$0.31+19.35%Beat+5.7%
    Mar 19
    Reported Apr 26
    		$0.45$0.38+18.42%Beat+67.7%
    Dec 18
    Reported Feb 14
    		$0.82$1.02-19.99%Miss+25.6%
    Sep 18
    Reported Nov 8
    		$0.36$0.37-2.70%Miss-35.7%
    Jun 18
    Reported Jul 26
    		$0.35$0.30+16.67%Beat-20.5%
    Mar 18
    Reported May 18
    		$0.27$0.35-23.31%Miss-46.3%
    Dec 17
    Reported Feb 2
    		$0.65$0.56+16.07%Beat+6.6%
    Sep 17
    Reported Nov 9
    		$0.56$0.57-1.75%Miss-
    Jun 17
    Reported Jul 27
    		$0.44$0.42+4.76%Beat-
    Mar 17
    Reported Apr 27
    		$0.50$0.54-7.41%Miss-
    Dec 16
    Reported Feb 2
    		$0.61$0.55+10.91%Beat-

    Dividends

    Dividend Metrics

    Forward Yield1.28%
    Forward Annual Dividend$2.14
    Payout Ratio12.08%
    FrequencySemi-Annual
    Pay MonthsFeb, Mar, Sep

    Growth

    3Y CAGR+3.29%
    5Y CAGR+2.40%
    AZN dividend history and ex-dividend datesRun AZN in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio23.06EV/EBITDA13.76x
    Price/FCF29.76xFCF Yield3.36%
    Profitability
    Profit Margin17.00%Operating Margin23.50%
    ROE22.00%ROIC14.92%
    Financial Health
    Debt/Equity0.59xInterest Coverage8.26x
    Current Ratio0.89xQuick Ratio0.67x
    Trading Statistics
    Beta0.21Avg Volume2.87M
    52-Week High$209.1152-Week Low$152.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$159.31
    SMA 20$161.98
    SMA 50$162.03
    SMA 200$179.80
    EMA 10$160.85
    EMA 20$161.21
    EMA 50$163.52
    EMA 200$170.95

    MACD

    Line: -0.70Signal: -1.12Hist: 0.41

    ADX

    ADX: 18.2+DI: 28.3-DI: 25.9

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down92.0
    PSAR$154.00

    Bollinger Bands

    Upper Band$170.29
    Lower Band$153.67
    %B Position1026%(Upper)
    Band Width0.79

    RSI (14-Day)

    Neutral
    58.7

    Momentum Oscillators

    Stoch %K51.1
    Stoch %D36.1
    Williams %R-19.5
    ROC (10d)5.7%
    Momentum9.03
    CCI (20d)98.2
    MFI (14d)40.7

    Volatility Measures

    ATR (14d)$3.86(2.3%)
    StdDev (20d)4.15
    Hist Vol26.5%(Moderate)

    Volume Flow

    VWAP$167.68
    OBV111.7M
    AD Line139.6B
    CMF (20d)-0.206

    Volume Metrics

    Avg Vol (20d)2.8M
    Vol Ratio1.5x(High)
    VWMA (20d)$161.97

    Pivot Points

    R3$168.12
    R2$165.42
    R1$163.72
    Pivot Point$161.02
    S1$159.32
    S2$156.62
    S3$154.92

    Advanced Oscillators

    TSI-5.27
    Ultimate Osc52.8
    KST-19.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$15.38B$15.29B$15.50B$15.19B$14.46B$13.59B$13.59B$14.89B$13.56B$12.94B$12.68B$12.02B
    Cost of Revenue$2.52B$2.68B$3.12B$2.80B$2.47B$2.24B$2.24B$2.73B$3.08B$2.18B$2.22B$2.31B
    Gross Profit$12.86B$12.61B$12.38B$12.39B$11.98B$11.35B$11.35B$12.17B$10.48B$10.76B$10.46B$9.72B
    Operating Expenses$9.70B$8.36B$9.41B$8.81B$8.48B$7.67B$7.67B$10.13B$8.38B$8.01B$7.35B$8.48B
    R&D$4.05B$3.49B$3.86B$3.66B$3.55B$3.16B$3.16B$4.68B$3.12B$3.01B$2.78B$3.07B
    SG&A$5.65B$4.92B$5.49B$5.08B$4.86B$4.49B$4.63B$5.41B$5.14B$4.93B$4.50B$5.37B
    Operating Income$3.16B$4.25B$2.98B$3.58B$3.51B$3.67B$3.67B$2.04B$2.11B$2.75B$3.12B$1.23B
    Interest Income$80.00M$73.00M$135.00M$85.00M$68.00M$84.00M$84.00M$64.00M$183.00M$0$0$0
    Interest Expense$435.00M$393.00M$472.00M$434.00M$439.00M$349.00M$349.00M$429.00M$457.00M$443.00M$413.00M$445.00M
    Income Before Tax$2.80B$3.91B$2.63B$3.24B$3.13B$3.40B$3.40B$1.67B$1.83B$2.40B$2.80B$897.00M
    Income Tax Expense$291.00M$833.00M$300.00M$709.00M$679.00M$481.00M$481.00M$166.00M$395.00M$469.00M$620.00M$-62,000,000
    Net Income$2.51B$3.08B$2.33B$2.53B$2.45B$2.92B$2.92B$1.50B$1.43B$1.93B$2.18B$960.00M
    EBITDA$5.16B$5.67B$4.63B$5.23B$4.96B$5.04B$5.04B$2.81B$4.10B$4.12B$4.47B$2.67B
    EBIT$3.23B$4.31B$3.10B$3.68B$3.57B$3.75B$3.75B$2.10B$2.29B$2.84B$3.21B$1.34B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AZN

    Government Contracts

    Gov Obligations (TTM)
    $733852
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    103.1%
    Active Awards
    4
    New Awards (TTM)
    3
    Avg Remaining Term
    4.6 mo

    Top agency: Department of Veterans Affairs at 99.9% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0055Department of Veterans AffairsDepartment of Veterans Affairs$1.26MDec 22, 2025
    36C24526N0739Department of Veterans AffairsDepartment of Veterans Affairs$104650Jul 21, 2026
    SPE2D026F0023Department of DefenseDefense Logistics Agency$500Nov 3, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    AstraZeneca PLC Stock (AZN) Moved Up by 3.55% on Oct 15: What Signal Does It Send?

    AstraZeneca PLC (AZN) saw its stock rise by 3.55% on October 15th, outperforming the Pharmaceuticals & Medical Research sector. This surge was primarily driven by a new strategic AI drug discovery partnership...

    TradingKey•10/15/26•Bullish

    RBC keeps AstraZeneca at ‘outperform’ ahead of AVANZAR lung cancer trial

    RBC Capital Markets has maintained its 'outperform' rating and 14,500p target price for AstraZeneca PLC, anticipating a quiet third quarter before results on October 30th. The firm forecasts revenues of $16.3 billion...

    Proactive financial news•10/15/26•Bullish

    AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal

    AstraZeneca has partnered with AI-driven drug developer Insitro to discover new treatments for complex liver and heart diseases like MASH and cardiomyopathies. Insitro will leverage its Virtual Human AI platform...

    Benzinga•10/15/26•Bullish

    The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk

    The Zacks Analyst Blog features research reports on Mastercard (MA), AstraZeneca (AZN), and Sandisk (SNDK). It provides an "Outperform" rating for Sandisk due to AI demand and strong cash generation...

    The Globe and Mail•10/15/26•Somewhat-Bullish

    AstraZeneca PLC Draws Bullish Targets As Oncology Deals Mount

    AstraZeneca PLC (AZN) has seen its stock rise by 4.04% due to promising trial data and bullish analyst upgrades from Nordea and Citi, driven by its strengthening drug pipeline...

    StocksToTrade•10/14/26•Bullish

    AZN Valuation and Fair Value

    P/E
    23.1x
    Forward P/E
    14.6x
    EV/EBITDA
    13.8x
    P/FCF
    29.8x
    PEG
    1.2x
    P/B
    5.2x
    See GNG's fair value

    AZN Profitability: Margins, ROIC and FCF

    Gross margin
    81.9%
    Operating margin
    23.5%
    Net margin
    17.0%
    ROIC
    14.9%
    ROE
    22.0%
    FCF margin
    14.2%
    FCF yield
    3.4%

    AZN Competitors

    CompanyTicker
    Novartis AG ADRNVS
    Thermo Fisher Scientific IncTMO
    UnitedHealth Group IncorporatedUNH
    Amgen IncAMGN
    Merck & Company IncMRK
    Gilead Sciences IncGILD
    AbbVie IncABBV
    Abbott LaboratoriesABT

    Sector: Healthcare

    AZN Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    3
    Buy
    7
    Hold
    1
    Sell
    0
    Strong Sell
    0

    AZN Bull Case vs Bear Case

    Bull case

    • AZN beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 90.9% of AZN's analyst ratings are Buy or Strong Buy.

    AZN Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    2.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $1.15
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    AZN Dividend

    Forward yield
    1.3%
    Payout ratio
    12.1%
    3Y DPS growth
    3.3%
    5Y DPS growth
    2.4%
    Pay months
    Feb, Mar, Sep
    AZN dividend history

    Frequently Asked Questions About AZN

    What is AZN's current dividend yield?

    AstraZeneca PLC (AZN) has a forward dividend yield of 1.28%.

    Does AZN pay dividends?

    Yes, AstraZeneca PLC pays dividends with a forward dividend yield of 1.28%.

    What is AZN's P/E ratio?

    AstraZeneca PLC has a price-to-earnings (P/E) ratio of 23.06.

    What is AZN's market cap?

    AstraZeneca PLC (AZN) has a market capitalization of $251.29B with a current stock price of $166.73.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In